Tarveda Therapeutics scores $38 mln Series C
Tarveda Therapeutics (formerly known as Blend Therapeutics) has raised $38 million in Series C funding. Novo A/S and return backer New Enterprise Associates led the round. The other investors included Flagship Ventures, NanoDimension and Eminent Venture Capital. In conjunction with the financing, Nilesh Kumar of Novo Ventures (US) Inc. and Dr. Frank Torti of NEA have been added to Tarveda’s board of directors while Drew Fromkin has been appointed interim board chairman.Watertown, Massachusetts-based Tarveda is a biopharmaceutical company focused on treating patients with solid tumor cancers.
27 January 2016•4 mins read
